Answers are grounded in this paper and cite their sources.
Literature review shows haloperidol-induced QT prolongation risk in psychiatric patients, highlighting the preventive utility of predictive pharmacogenetic testing.
Relevance. Antipsychotics are widely used in psychiatry. Haloperidol remains one of the most commonly used antipsychotics because of its effectiveness. However, it has various adverse reactions, including an increased risk of QT prolongation, a potentially fatal complication that can lead to Torsade de Pointes and sudden cardiac death. Objective. To systematize information for practicing psychiatrists and clinical pharmacologists regarding a personalized approach to the prevention of QT interval prolongation in patients with mental disorders who are taking haloperidol. Methods. A search for full-text articles published from 02/01/2013 to 02/01/2024 was conducted using PubMed, eLIBRARY.RU, and Google Scholar. Results. This short review analyzes and summarizes the results of foreign and domestic studies on the effect of haloperidol on the QT interval, the role of risk factors and hereditary predisposition in the development of haloperidol-induced prolongation of the QT interval, and Torsade de Pointes in patients with mental disorders. The main mechanism of the cardiotoxic effect of haloperidol is the dose-dependent inhibition of potassium channels in the cardiomyocyte membrane. Haloperidol is extensively metabolized in the liver, which may cause significant interindividual variability in its pharmacokinetics. A decrease in the metabolism rate of haloperidol may lead to an increase in its concentration in the blood, thereby increasing the risk of developing cardiotoxic adverse reactions. To reduce the risk of developing haloperidol-induced prolongation of the QT interval, it is advisable to use predictive pharmacogenetic testing. Conclusion. Generalized data on the effect of haloperidol on the duration of the QT interval and the risk of developing TdP in patients with mental disorders may be required by psychiatrists and clinical pharmacologists when selecting the dose and duration of haloperidol administration. Predictive pharmacogenetic testing can help reduce the incidence of potentially fatal cardiotoxic adverse reactions.
No takes yet. Share an insight, caveat, or question.
Насырова et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: